A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at the European Society of Cardiology (ESC) Congress, held ...

The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason. In the ABYSS ...

Credit: Getty Images. A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. The role of beta-blockers after acute ...

Our findings in a large, population-based registry of over 20 000 patients with a recent hospitalization for documented HF suggest that prescription of a non-selective beta-blocker is associated with ...

Please provide your email address to receive an email when new articles are posted on . Optimal duration of beta-blockers after a heart attack remains unknown. The ABYSS trial provides new insights on ...

Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms, left ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Beta-blocker use did not reduce risk for death or new MI ...

The cardiovascular safety of an interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the ...

Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...